Antithrombotic therapy in atrial fibrillation

Clinics in Geriatric Medicine

Volumn 22, Issue 1, 2006, Pages 155-166

  Garcia, David A ^a   Hylek, Elaine M ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; IDRAPARINUX; IRBESARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SULFINPYRAZONE; THROMBIN INHIBITOR; TICLOPIDINE; WARFARIN; XIMELAGATRAN;

ARTICLE; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FALLING; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HUMAN; PATIENT; POPULATION RESEARCH; RISK ASSESSMENT; SIDE EFFECT; SINUS RHYTHM;

EID: 29244478881     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2005.09.011     Document Type: Review

References (55)

1. A.S. Go, E.M. Hylek, and K.A. Phillips Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375
2. D.M. Lloyd-Jones, T.J. Wang, and E.P. Leip Lifetime risk for development of atrial fibrillation: the Framingham Heart Study Circulation 110 2004 1042 1046
3. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
4. H.J. Lin, P.A. Wolf, and M. Kelly-Hayes Stroke severity in atrial fibrillation: the Framingham Study Stroke 27 1996 1760 1764
5. E.M. Hylek, A.S. Go, and Y. Chang Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 2003 1019 1026
6. N. Spratt, Y. Wang, and C. Levi A prospective study of predictors of prolonged hospital stay and disability after stroke J Clin Neurosci 10 2003 665 669
7. The European Atrial Fibrillation Trial Study Group Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia N Engl J Med 333 1995 5 10
8. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation N Engl J Med 323 1990 1505 1511
9. The Stroke Prevention in Atrial Fibrillation Investigators Stroke Prevention in Atrial Fibrillation Study. Final results Circulation 84 1991 527 539
10. S.J. Connolly, A. Laupacis, and M. Gent Canadian Atrial Fibrillation Anticoagulation (CAFA) Study J Am Coll Cardiol 18 1991 349 355
11. M.D. Ezekowitz, S.L. Bridgers, and K.E. James Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators N Engl J Med 327 1992 1406 1412
12. P. Petersen, G. Boysen, and J. Godtfredsen Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study Lancet 1 1989 175 179
13. R.G. Hart, O. Benavente, and R. McBride Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 1999 492 501
14. The Stroke Prevention in Atrial Fibrillation Investigators Bleeding during antithrombotic therapy in patients with atrial fibrillation Arch Intern Med 156 1996 409 416
15. A.S. Go, E.M. Hylek, and Y. Chang Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290 2003 2685 2692
16. B.F. Gage, M. Boechler, and A.L. Doggette Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation Stroke 31 2000 822 827
17. M.C. Fang, R.S. Stafford, and J.N. Ruskin National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation Arch Intern Med 164 2004 55 60
18. A.S. Go, E.M. Hylek, and L.H. Borowsky Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Ann Intern Med 131 1999 927 934
19. N.L. Smith, B.M. Psaty, and C.D. Furberg Temporal trends in the use of anticoagulants among older adults with atrial fibrillation Arch Intern Med 159 1999 1574 1578
20. R.H. White, M.A. McBurnie, and T. Manolio Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort Am J Med 106 1999 165 171
21. N. Cohen, D. Almoznino-Sarafian, and I. Alon Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission Stroke 31 2000 1217 1222
22. T.J. Bungard, W.A. Ghali, and K.K. Teo Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 160 2000 41 46
23. S.F. Jencks, T. Cuerdon, and D.R. Burwen Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels JAMA 284 2000 1670 1676
24. The Stroke Prevention in Atrial Fibrillation Investigators Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study Lancet 343 1994 687 691
25. V. Pengo, C. Legnani, and F. Noventa Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding: a Multicenter Inception Cohort Study Thromb Haemost 85 2001 418 422
26. E.M. Hylek, and D.E. Singer Risk factors for intracranial hemorrhage in outpatients taking warfarin Ann Intern Med 120 1994 897 902
27. F.H. Steffensen, K. Kristensen, and E. Ejlersen Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort J Intern Med 242 1997 497 503
28. F.J. van der Meer, F.R. Rosendaal, and J.P. Vandenbroucke Bleeding complications in oral anticoagulant therapy: an analysis of risk factors Arch Intern Med 153 1993 1557 1562
29. C.S. Landefeld, M.W. Rosenblatt, and L. Goldman Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions Am J Med 87 1989 153 159
30. G.W. Albers, H.C. Diener, and L. Frison Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 2005 690 698
31. S.B. Olsson Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
32. A.M. Wodlinger, and J.A. Pieper The role of clopidogrel in the management of acute coronary syndromes Clin Ther 25 2003 2155 2181
33. G. Opolski, A. Torbicki, and D.A. Kosior Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study Chest 126 2004 476 486
34. D.G. Wyse, A.L. Waldo, and J.P. DiMarco A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825 1833
35. I.C. Van Gelder, V.E. Hagens, and H.A. Bosker A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation N Engl J Med 347 2002 1834 1840
36. S.H. Hohnloser, K.H. Kuck, and J. Lilienthal Rhythm or rate control in atrial fibrillation. Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial Lancet 356 2000 1789 1794
37. J. Carlsson, S. Miketic, and J. Windeler Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study J Am Coll Cardiol 41 2003 1690 1696
38. S. de Denus, C.A. Sanoski, and J. Carlsson Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis Arch Intern Med 165 2005 258 262
39. D.E. Singer, G.W. Albers, and J.E. Dalen Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 3 Suppl 2004 429S 456S
40. G. Palareti, N. Leali, and S. Coccheri Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy Lancet 348 1996 423 428
41. R.G. Hart, L.A. Pearce, and R. McBride Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators Stroke 30 1999 1223 1229
42. B.F. Gage, A.D. Waterman, and W. Shannon Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
43. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
44. C. van Walraven, R.G. Hart, and G.A. Wells A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin Arch Intern Med 163 2003 936 943
45. T.J. Wang, J.M. Massaro, and D. Levy A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study JAMA 290 2003 1049 1056
46. D. Massel, and S.H. Little Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis J Am Coll Cardiol 37 2001 569 578
47. M. Battistella, M.M. Mamdami, and D.N. Juurlink Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors Arch Intern Med 165 2005 189 192
48. M.M. Wolfe, D.R. Lichtenstein, and G. Singh Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N Engl J Med 340 1999 1888 1899
49. I. Mahe, N. Bertrand, and L. Drouet Paracetamol: a haemorrhagic risk factor in patients on warfarin Br J Clin Pharmacol 59 2005 371 374
50. H.H. Thijssen, B.A. Soute, and L.M. Vervoort Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle Thromb Haemost 92 2004 797 802
51. C. Pappone, S. Rosanio, and G. Augello Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study J Am Coll Cardiol 42 2003 185 197
52. J.L. Blackshear, and J.A. Odell Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation Ann Thorac Surg 61 1996 755 759
53. T. Sueda, K. Imai, and O. Ishii Efficacy of pulmonary vein isolation for the elimination of chronic atrial fibrillation in cardiac valvular surgery Ann Thorac Surg 71 2001 1189 1193
54. H. Oral, B.P. Knight, and H. Tada Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation Circulation 105 2002 1077 1081
55. H. Sievert, M.D. Lesh, and T. Trepels Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience Circulation 105 2002 1887 1889